Phillip Mease

197PUBLICATIONS
307CO-AUTHORS
Exercise physiologyRheumatology and arthritisPharmacogenomicsProsthetics and orthoticsToxicology (incl. clinical toxicology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (197)

|Nov 11, 2026
Durable and Additive Disease Control at 52 Weeks With Ixekizumab Plus Tirzepatide Versus Ixekizumab Alone in Adults With Psoriatic Arthritis and Obesity or Overweight: Additional Results From a Randomized Clinical Trial.

|Oct 20, 2026
Sustained Inhibition of Structural Damage Progression and Improvements in Disease Activity With Guselkumab in Biologic-Naïve Participants with Active and Erosive Psoriatic Arthritis: Results Through Week 48 of the Phase 3b Randomized, Double-Blind, Placebo-Controlled APEX Study.

|Oct 11, 2026
Bimekizumab efficacy across GRAPPA domains to 3 years in patients with psoriatic arthritis: a post hoc analysis of two phase 3 studies.

|Sep 25, 2026
Comparative analysis of instruments measuring peripheral arthritis activity in Spondyloarthritis: a measurement properties study in 13 RCTs.

|Aug 27, 2026
Efficacy and safety of upadacitinib in patients with psoriatic arthritis and exposure to one anti-TNF: post hoc analysis of SELECT-PsA 2.

|Jul 20, 2026
Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial.

Pageof 33

Frequent Collaborators

43 joint publications

Laura C Coates

39 joint publications

Dafna Gladman

29 joint publications

Philip S Helliwell

23 joint publications

Oliver FitzGerald